Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02653417
Recruitment Status : Unknown
Verified November 2016 by Radius Health, Inc.. Recruitment status was: Active, not recruiting
The objectives of this study are to determine the safety and efficacy of RAD1901 in postmenopausal women with moderate to severe VMS as assessed by a reduction from baseline in the frequency and severity of hot flashes [ Time Frame: 12 Weeks ]
Secondary Outcome Measures :
Change from baseline in the severity of hot flashes at 4 and 12 weeks [ Time Frame: 4 and 12 weeks ]
Change from baseline in the frequency of moderate to severe hot flashes at 4 weeks [ Time Frame: 4 weeks ]
Change from baseline in the frequency of mild, moderate, and severe hot flashes at 4 and 12 weeks by eDiary [ Time Frame: 4 and 12 weeks ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
40 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
To participate in this study, a subject MUST:
be a postmenopausal woman between 40 and 65 years of age, inclusive
be seeking relief or treatment for moderate to severe VMS
be willing to discontinue and abstain from the following: vaginal hormonal products; transdermal or oral estrogen or estrogen/progestin combination; progestin implants; injectable estrogen; topical progesterone cream, selective estrogen receptor modulators [e.g., ospemifene, raloxifene, tamoxifen, Duavee® (conjugated estrogens and bazedoxifene) and intrauterine devices (IUDs)]
have a normal or clinically insignificant transvaginal ultrasound (TVU)
have a normal endometrial biopsy subsequent to the TVU without clinically relevant results
have a normal screening Papanicolaou (Pap) smear
have a mammogram within 9 months prior to randomization. Subjects must have a Breast Imaging Reporting and Data System (BI-RADS) mammography result of 1 or 2 to enroll.
Subjects with any of the following characteristics will not be eligible to participate in the study:
have a history of invasive breast cancer or ductal carcinoma in situ, melanoma or any gynecologic cancer.
using any of the following:
oral estrogen-, progestin-, androgen-, or selective estrogen receptor modulator containing drug products within 8 weeks before screening (visit 1)
transdermal hormone products within 4 weeks before screening (visit 1)
vaginal hormone products (rings, creams, gels) within 4 weeks before screening (visit 1)
progestin implants/injectables, IUDs or estrogen pellets/injectables within 6 months before screening (visit 1)
have been treated with a GnRH agonist within the last year
have been treated with anti-estrogens, or aromatase inhibitors within 2 months prior to study entry
have been concurrently treated and will abstain from gabapentin and paroxetine or serotonin and norepinephrine reuptake inhibitors (SNRIs) for VMS or other indications for 3 months during the trial and have not taken within 4 weeks prior to screening
have an endometrial biopsy at baseline with a diagnosis by a gynecologic pathologist of proliferative, hyperplasia, polyp or cancer
unresolved findings suspicious for malignancy on the breast examination